Trials
1 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “NEO212 is a novel chemical entity that was generated by covalent conjugation of temozolomide (TMZ) with perillyl alcohol (POH).”In the company’s words, NCT06047379 on ClinicalTrials.gov
- Tested for
- Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype, Brain Metastases, Adult, Cervical Cancer, Colorectal Cancer, Esophageal Cancer, Esophageal Squamous Cell Carcinoma, Gastric Cancer and 13 more
- Main trialPhase 1/2
- “This multi-site, Phase 1/2 clinical trial is an open-label study to identify the safety, pharmacokinetics, and efficacy of a repeated dose regimen of NEO212 alone for the treatment of patients with radiographically-confirmed progression of Astrocytoma IDH- mutant, Glioblastoma IDH-wildtype, and the safety, pharmacokinetics and efficacy of a repeated dose regimen of NEO212 when given with select SOC for the treatment of solid tumor patients with radiographically confirmed uncontrolled metastases to the brain. The study will have three phases, Phase 1, Phase 2a and Phase 2b.”In the company’s words, NCT06047379 on ClinicalTrials.gov
- Other names
- POH-TMZ
Other drugs for Glioblastoma, IDH-wildtype
- 131I-IPATelix Pharmaceuticals (Innovations) Pty Limited · Phase 3
- SafusidenibNuvation Bio · Phase 3
- Cerebraca waferEverfront Biotech Co., Ltd. · Phase 2/3
- PembrolizumabMerck & Co. · Phase 3
- LAM561Laminar Pharmaceuticals · Phase 2/3
- VebreltinibBeijing Pearl Biotechnology Limited Liability Company · Phase 2/3
Coming up1
- 28 Feb 2027Phase 1/2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Recruiting | 28 Feb 2027 | Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 20 Nov 2026 · EU trials register (CTIS) updated 20 Nov 2026 · openFDA updated 20 Nov 2026